Your browser is no longer supported. Please, upgrade your browser.
CYAD Celyad Oncology SA monthly Stock Chart
CYAD [NASD]
Celyad Oncology SA
Index- P/E- EPS (ttm)- Insider Own- Shs Outstand- Perf Week12.94%
Market Cap- Forward P/E- EPS next Y- Insider Trans- Shs Float- Perf Month31.09%
Income- PEG- EPS next Q- Inst Own- Short Float- Perf Quarter-2.45%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio33.68 Perf Half Y-20.18%
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year-14.00%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range4.10 - 13.01 Perf YTD-4.51%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-23.52% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low142.68% ATR0.34
Employees105 Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)65.29 Volatility1.27% 3.15%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume1.77 Prev Close9.63
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume6.36K Price9.95
Recom- SMA2014.20% SMA5012.14% SMA2005.99% Volume11,232 Change3.32%
Jul-05-19Reiterated H.C. Wainwright Buy $52 → $48
May-25-18Initiated Wells Fargo Outperform $44
Nov-10-20 04:01PM  
Nov-04-20 04:01PM  
Nov-02-20 04:01PM  
Sep-29-20 05:53PM  
07:47AM  
01:00AM  
Sep-23-20 04:01PM  
Sep-22-20 04:01PM  
Sep-14-20 01:00AM  
Aug-26-20 01:00AM  
01:00AM  
Aug-06-20 04:01PM  
Aug-03-20 01:00AM  
01:00AM  
Jul-15-20 10:34AM  
Jul-14-20 01:00AM  
01:00AM  
Jun-10-20 01:00AM  
Jun-01-20 01:00AM  
May-27-20 09:34AM  
May-26-20 01:00AM  
May-25-20 12:00PM  
May-24-20 07:00AM  
May-07-20 01:00AM  
May-06-20 01:00AM  
Apr-30-20 01:00AM  
Apr-22-20 01:00AM  
Apr-20-20 09:06AM  
Mar-31-20 12:00PM  
Mar-26-20 04:42AM  
Mar-25-20 11:00AM  
Mar-24-20 07:36PM  
Mar-12-20 04:01PM  
Mar-02-20 01:00AM  
Feb-17-20 01:00AM  
Jan-13-20 01:00AM  
Dec-10-19 03:21AM  
Dec-09-19 06:30PM  
Dec-07-19 08:35AM  
Dec-06-19 01:33AM  
01:00AM  
Dec-03-19 07:05AM  
Nov-29-19 01:00AM  
Nov-22-19 08:18AM  
01:00AM  
Nov-19-19 01:00AM  
01:00AM  
Nov-13-19 09:00AM  
Nov-11-19 01:00AM  
Nov-06-19 09:00AM  
Nov-05-19 08:00AM  
08:00AM  
Nov-03-19 10:51AM  
Oct-22-19 12:34AM  
Oct-02-19 01:00AM  
01:00AM  
Sep-16-19 04:01PM  
Sep-12-19 09:56AM  
09:28AM  
Sep-11-19 07:09AM  
Sep-10-19 04:01PM  
Sep-04-19 02:42AM  
01:00AM  
Aug-29-19 01:00AM  
Aug-22-19 04:00PM  
01:20AM  
Aug-16-19 01:00AM  
Jul-15-19 09:17AM  
Jul-05-19 08:55AM  
03:21AM  
Jul-02-19 04:01PM  
07:29AM  
Jul-01-19 04:01PM  
Jun-21-19 08:45AM  
Jun-17-19 04:32PM  
Jun-03-19 06:48AM  
May-29-19 01:00AM  
May-16-19 04:01PM  
May-09-19 01:00AM  
May-02-19 04:01PM  
Apr-17-19 04:01PM  
Apr-01-19 04:01PM  
Mar-28-19 04:05PM  
04:01PM  
Mar-18-19 04:01PM  
Mar-11-19 02:00AM  
Mar-08-19 01:00AM  
Feb-21-19 04:01PM  
Jan-07-19 01:00AM  
Dec-04-18 01:45AM  
Nov-30-18 08:25AM  
01:00AM  
Nov-21-18 01:00AM  
Nov-15-18 01:00AM  
Nov-09-18 12:45PM  
Nov-01-18 09:01AM  
Oct-05-18 08:48AM  
Oct-04-18 01:03AM  
01:00AM  
Sep-28-18 01:00AM  
Celyad Oncology, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies for the treatment of cancer. The company's lead drug product candidates include CYAD-01 and CYAD-02 autologous cell therapies, which are in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia. It is also developing CYAD-101, an allogeneic cell therapy that is in Phase I clinical trial for the treatment of metastatic colorectal cancer; and CYAD-103, an allogeneic CAR-T product candidate that is in preclinical development for the treatment of solid tumors. The company's other preclinical candidates include CYAD-211, a CAR-T candidate targeting B-cell maturation antigen for the treatment of multiple myeloma; CYAD-221, a CAR-T candidate targeting CD19 for the treatment of B-cell malignancies; and CYAD-231, a dual specific CAR-T candidate targeting NKG2D and an undisclosed membrane protein. Celyad Oncology has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Cardio3 BioSciences SA and changed its name to Celyad SA in May 2015. Celyad Oncology was founded in 2004 and is based in Mont-Saint-Guibert, Belgium.